

16. Lathia, C. D. Biomarkers and Surrogate Endpoints: How and when Might They Impact Drug Development? *Dis. Markers* **2002**, *18*, 83–90.
17. a. Schou, M.; Pike, V. W.; Halldin, C. Development of Radioligands for Imaging of Brain Norepinephrine Transporters *in Vivo* with Positron Emission Tomography. *Curr. Top. Med. Chem.* **2007**, *7* (18), 1806–1816.
b. Paterson, L. M.; Kornum, B. R.; Nutt, D. J.; Pike, V. W.; Knudsen, G. M. 5-HT Radioligands for Human Brain Imaging with PET and SPECT. *Med. Res. Rev.* **2013**, *33* (1), 54–111.
c. Lever, J. R. PET and SPECT Imaging of the Opioid System: Receptors, Radioligands and Avenues for Drug Discovery and Development. *Curr. Pharm. Des.* **2007**, *13* (1), 33–49.
18. a. Mu, J.; Woods, J.; Zhou, Y. P.; Roy, R. S.; Li, Z.; Zycband, E.; Feng, Y.; Zhu, L.; Li, C.; Howard, A. D.; et al. Chronic Inhibition of Dipeptidyl Peptidase-4 with a Sitagliptin Analog Preserves Pancreatic B-cell Mass and Function in a Rodent Model of Type 2 Diabetes. *Diabetes* **2006**, *55*, 1695–1704.
b. Aschner, P.; Kipnes, M. S.; Lunceford, J. K.; Sanchez, M.; Mickel, C.; Williams-Herman, D. E. Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients with Type 2 Diabetes. *Diabetes Care* **2006**, *29* (12), 2632–2637.
19. a. Cox, C. D.; Breslin, M. J.; Whitman, D. B.; Schreier, J. D.; McGaughey, G. B.; Bogusky, M. J.; Roecker, A. J.; Mercer, S. P.; Bednar, R. A.; Lemaire, W.; et al. Discovery of the Dual Orexin Receptor Antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia. *J. Med. Chem.* **2010**, *53* (14), 5320–5332.
b. Winrow, C. J.; Gotter, A. L.; Cox, C. D.; Doran, S. M.; Tannenbaum, P. L.; Breslin, M. J.; Garson, S. L.; Fox, S. V.; Harrell, C. M.; Stevens, J.; et al. Promotion of Sleep by Suvorexant – A Novel Dual Orexin Receptor Antagonist. *J. Neurogenet.* **2011**, *25* (1–2), 52–61.
20. a. Sanguinetti, M. C.; Jiang, C.; Curran, M. E.; Keating, M. T. A Mechanistic Link between an Inherited and an Acquired Cardiac Arrhythmia: HERG Encodes the IKr Potassium Channel. *Cell* **1995**, *81* (2), 299–307.
b. Sanguinetti, M. C.; Tristani-Firouzi, M. hERG Potassium Channels and Cardiac Arrhythmia. *Nature* **2006**, *440* (7083), 463–469.
21. Mayeux, R. Biomarkers: Potential Uses and Limitations. *NeuroRx J. Am. Soc. Exp. Neurother.* **2004**, *1*, 182–188.
22. Iwatsubo, T.; Hirota, N.; Ooie, T.; Suzuki, H.; Shimada, N.; Chiba, K.; Ishizaki, T.; Green, C. E.; Tyson, C. A.; Sugiyama, Y. Prediction of *in Vivo* Drug Metabolism in the Human Liver from *in Vitro* Metabolism Data. *Pharmacol. Ther.* **1997**, *73* (2), 147–171.
23. Hidalgo, I. J.; Raub, T. J.; Borchardt, R. T. Characterization of the Human Colon Carcinoma Cell Line (Caco-2) as a Model System for Intestinal Epithelial Permeability. *Gastroenterology* **1989**, *96* (3), 736–749.
24. Wittes, J.; Lakatos, E.; Probstfield, J. Surrogate Endpoints in Clinical Trials: Cardiovascular Diseases. *Statistics Med.* **1989**, *8*, 415–425.
25. Kanekar, A. Biomarkers Predicting Progression of Human Immunodeficiency Virus-related Disease. *J. Clin. Med. Res.* **2010**, *2* (2), 55–61.
26. a. Mozley, P. D.; Schwartz, L. H.; Bendtsen, C.; Zhao, B.; Petrick, N.; Buckler, A. J. Change in Lung Tumor Volume as a Biomarker of Treatment Response: A Critical Review of the Evidence. *Ann. Oncol.* **2010**, *21*, 1751–1755.
b. Zhao, B.; Oxnard, G. R.; Moskowitz, C. S.; Kris, M. G.; Pingzhen, W. P.; Rusch, V. M.; Ladanyi, M.; Rizvi, N. A.; Schwartz, L. H. A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development. *Clin. Cancer Res.* **2010**, *16*, 4647–4653.
c. Kogan, A. J.; Haren, M. Translating Cancer Trial Endpoints into the Language of Managed Care. *Biotechnol. Healthc.* **2008**, *5* (1), 22–35.